

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd. *

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02607)

**CHANGE OF JOINT COMPANY SECRETARY
AND
AGENT FOR THE ACCEPTANCE OF SERVICE OF
PROCESS AND NOTICES IN HONG KONG**

The board of directors (the “**Board**”) of Shanghai Pharmaceuticals Holding Co., Ltd. (the “**Company**”) hereby announces that Ms. LEUNG Shui Bing (梁瑞冰) (“**Ms. Leung**”) applied to resign from the joint company secretary of the Company (the “**Joint Company Secretary**”) and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) due to adjustment of work arrangement, with effect from 20 February 2024. Ms. Leung has confirmed that there is no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company in relation to her resignation.

The Board is pleased to further announce that Ms. WONG Pui Kiu Ingrid (黃沛翹) (“**Ms. Wong**”) has been appointed by the Company as a Joint Company Secretary and the Process Agent, with effect from 20 February 2024. Mr. ZHONG Tao (鍾濤) (“**Mr. Zhong**”) will continue to serve as the other Joint Company Secretary.

Ms. Wong is currently a senior manager of Corporate Services of Tricor Services Limited, a global professional services provider specializing in integrated Business, Corporate and Investor Services. Ms. Wong has over 10 years’ experience in the corporate secretarial and legal advisory services. Ms. Wong holds a Master of Science degree in Corporate Governance and Compliance from the Hong Kong Baptist University, a Bachelor of Laws degree from The University of Law in London, the United Kingdom, and a Bachelor of Business Administration degree in Global Business and Management of Organizations from The Hong Kong University of Science and Technology. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute (HKCGI) and The Chartered Governance Institute (CGI) in the United Kingdom.

Ms. Wong meets the qualification requirements for a company secretary under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”), for a period from 20 February 2024 to 28 August 2025 (the “**Remaining Wavier Period**”) in relation to Mr. Zhong’s eligibility to act as the Joint Company Secretary on the conditions that (i) Mr. Zhong will be assisted by Ms. Wong during the Remaining Wavier Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes. Before the end of the Remaining Wavier Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Mr. Zhong, having had the benefit of Ms. Wong’s assistance during the Remaining Wavier Period, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Leung for her valuable contribution to the Company during her tenure as a Joint Company Secretary, and to express its welcome to Ms. Wong on her appointment as a Joint Company Secretary.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHONG Tao
Joint Company Secretary

Shanghai, the PRC, 22 December 2023

As of the date of this announcement, the executive directors of the Company are Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive directors are Mr. YAO Jiayong and Mr. CHEN Fashu; and the independent non-executive directors are Mr. GU Zhaoyang, Mr. Manson FOK and Mr. WANG Zhong.

** For identification purpose only*